Newcells Biotech

Executive Summary

Newcells Biotech is a UK-based preclinical-stage company that has developed proprietary in vitro tissue models using primary cells and induced pluripotent stem cells (iPSCs) to enhance drug discovery and development. Its platforms focus on physiologically relevant models of the retina, kidney, and lung, providing predictive data on drug efficacy, safety, and transport. Founded in 2015 and based in Newcastle upon Tyne, Newcells aims to reduce reliance on animal testing and improve clinical translation. The company operates in the cell therapy and regenerative medicine sectors, targeting high unmet needs in ophthalmology, nephrology, and respiratory diseases. Despite being privately held with no disclosed funding, Newcells has established a niche by addressing the gap between traditional 2D cell assays and complex in vivo systems, offering services to biopharma clients to de-risk preclinical pipelines. Newcells' technology has the potential to accelerate drug development for indications with poor preclinical-to-clinical correlation, such as age-related macular degeneration and chronic kidney disease. Its competitive advantage lies in the use of human primary and iPSC-derived cells that retain native tissue functionality, which may improve predictivity over animal models. The company is well-positioned to capitalize on increasing regulatory and industry push for more human-relevant models under the FDA Modernization Act 2.0 and similar initiatives. Near-term growth will depend on securing partnerships and further validation of its platforms. With a lean operation and focused portfolio, Newcells Biotech represents an early-stage opportunity in the evolving landscape of advanced in vitro models.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top-20 pharma company for retinal model validation60% success
• Q4 2026Series A funding round to scale manufacturing and expand lung model portfolio55% success
• Q2 2026Launch of a novel iPSC-derived kidney proximal tubule model for nephrotoxicity screening80% success